14.5 KB of tabular data containing hazard ratios for overall survival and progression-free interval across multiple cancer types, based on PRKD3 expression. The dataset was authored by Jocshan Loaiza-Moss and last updated on April 3, 2026. It is shared under a CC-BY-4.0 license on figshare.
Use Cases
- Identify cancers where PRKD3 expression is a significant prognostic biomarker based on hazard ratios.
- Compare the impact of PRKD3 on overall survival versus progression-free interval across pan-cancer cohorts.
- Validate or correlate PRKD3 biomarker findings with other genomic or immune infiltration data mentioned in the platform tags.
Strengths
- Data is focused on a specific, clinically relevant biomarker (PRKD3) for survival analysis.
- Includes both overall survival and progression-free interval metrics, providing a dual outcome perspective.
- Released under a permissive CC-BY-4.0 license for broad reuse.
Limitations
- The dataset is very small at 14.5 KB, indicating limited scope.
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count is unknown, which may limit suitability assessment.
Provenance
- Source
- figshare, author Jocshan Loaiza-Moss.
- Collection Method
- Likely derived from analysis of pan-cancer cohorts, such as The Cancer Genome Atlas (TCGA), as suggested by platform tags.
- Time Range
- null
- Freshness
- Last updated 2026-04-03 17:51:03; freshness should be verified.
- Geography
- null